{"id":"open-label-lofexidine-hcl","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"}]},"_chembl":{"chemblId":"CHEMBL17860","moleculeType":"Small molecule","molecularWeight":"259.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lofexidine binds to alpha-2 adrenergic receptors in the central nervous system, suppressing the release of norepinephrine and reducing the sympathomimetic symptoms of opioid withdrawal such as anxiety, irritability, and physical discomfort. By dampening the hyperactive noradrenergic state that occurs when opioids are discontinued, it alleviates withdrawal symptoms without producing euphoria or abuse potential.","oneSentence":"Lofexidine is an alpha-2 adrenergic agonist that reduces noradrenergic hyperactivity associated with opioid withdrawal.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:26.561Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid withdrawal syndrome"}]},"trialDetails":[{"nctId":"NCT06047834","phase":"PHASE2","title":"Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioCorRx Pharmaceuticals Inc","startDate":"2023-10-02","conditions":"Opioid Withdrawal (Disorder)","enrollment":24},{"nctId":"NCT01863186","phase":"PHASE3","title":"Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2013-06","conditions":"Opioid Dependence, Acute Opioid Withdrawal Syndrome","enrollment":603},{"nctId":"NCT02363998","phase":"PHASE3","title":"Open-Label, Safety Study of Lofexidine","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2015-02","conditions":"Opioid Withdrawal","enrollment":286},{"nctId":"NCT01437306","phase":"PHASE1","title":"Lofexidine Food Effect Study in Healthy Volunteers","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2011-10","conditions":"Healthy","enrollment":13},{"nctId":"NCT01629446","phase":"PHASE1","title":"Lofexidine Mass Balance in Volunteers","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2012-05","conditions":"Normal Healthy Volunteers","enrollment":6},{"nctId":"NCT01310296","phase":"PHASE1","title":"Lofexidine ADME & Mass Balance in Volunteers","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2011-07","conditions":"Normal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the Product","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Open Label Lofexidine HCL","genericName":"Open Label Lofexidine HCL","companyName":"USWM, LLC (dba US WorldMeds)","companyId":"uswm-llc-dba-us-worldmeds","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lofexidine is an alpha-2 adrenergic agonist that reduces noradrenergic hyperactivity associated with opioid withdrawal. Used for Opioid withdrawal syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}